Meeting
2023 ASCO Genitourinary Cancers Symposium
DNA alterations in papillary renal cancer.
Authors
Francesca Jackson-Spence
Barts Cancer Institute, London, United Kingdom
Francesca Jackson-Spence , Charlotte Ackerman , Bernadett Szabados , Charlotte Toms , Agne Jovaisaite , Rachel Gunnell , Cristina Suárez , James Larkin , Poulam Patel , Begoña Pérez Valderrama , Alejo Rodriguez-Vida , Hilary Glen , Fiona C. Thistlethwaite , Christy Ralph , Gopalakrishnan Srinivasan , Maria Jose Mendez-Vidal , Aleksandra Markovets , Ryan James Hartmaier , Thomas Powles
Organizations
Barts Cancer Institute, London, United Kingdom, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom, Barts Health NHS Trust, London, United Kingdom, Vall d’Hebron Institute of Oncology, Barcelona, Spain, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom, Hospital Universitario Virgen del Rocío (Spain), Sevilla, Spain, Medical Oncology Department, Hospital del Mar Research Institute, Barcelona, Spain, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom, Christie Hospital, Manchester, United Kingdom, University of Leeds, Leeds, United Kingdom, Mid Essex Hospital Services NHS Trust, Broomfield, United Kingdom, Hospital Reina Sofia, Cordoba, Spain, Oncology Bioscience, IMED Biotech Unit, AstraZeneca, Boston, MA, AstraZeneca R&D Boston, Waltham, MA
Research Funding
Pharmaceutical/Biotech Company
AstraZeneca
Background: The characterisation of DNA alternations in papillary renal cancer (PRC) is unclear. The CALYPSO trial (NCT02819596) prospectively evaluated combination therapy of savolitinib (MET inhibitor) and durvalumab (PD-L1 inhibitor) in PRC. The trial showed high response rates (RR) in the MET-driven population. Here we explore the relationship between MET, PD-L1 and TMB in these tumours and the relevance of other biomarkers including PIK3CA, PTEN and KRAS. Methods: FoundationOne analysis from 41 samples of PRC patients enrolled on the CALYPSO trial was performed. The relevance of co-positivity between MET/PD-L1 and MET/TMB as well as analysis of other DNA alterations such as PIK3CA, PTEN and KRAS was explored. Outcome parameters were correlated with RR, PFS and OS. Results: 41% of patients were MET-driven, 66% were PD-L1+ (vCPS≥1) and 3% were TMB >10mut/Mb. Further testing used TMB ≥ median (2.52mut/Mb) 32% of patients were both MET-driven and PD-L1+. 17% of patients were both MET-driven and TMB ≥ median. RR and survival outcomes for combinations are shown in the table. The overall RR in MET driven and non-MET-driven patients was 52.9% and 13%, respectively. The median PFS and OS in the MET-driven group was 12.0 months (95% CI: 2.9-19.4) and 27.4 months (95% CI: 9.3-not reached [NR]), respectively, compared to a median PFS and OS in the non-MET-driven group of 2.7 months (95% CI: 0.5-5.0) and 7.5 months (95% CI: 0.0-16.0), respectively. PIK3CA, PTEN and KRAS mutations occurred in 1, 4 and 2 patients, with RR of 0% (0/1), 25% (1/4) and 50% (1/2), in the PIK3CA, PTEN and KRAS groups, respectively. Conclusions: MET-driven papillary cancers have low mutational burden, but high PD-L1 expression. Small patient numbers limit definitive conclusions, but responses occur irrespective of the immune biomarkers investigated. Other DNA alterations are rare and did not appear to influence outcomes in this cohort. These data support the design of the SAMETA trial (NCT05043090), further investigating the savolitinib and durvalumab combination.
| RR % (n) | Median PFS (months) | Median OS (months) | |
|---|---|---|---|
| MET-driven/PD-L1+ | 46% (6/13) | 12.0 (95% CI: 7.6-16.3) | 21.3 (95% CI: 10.4-32.1) |
| MET-driven/PD-L1- | 67% (2/3) | 16.7 (95% CI: 7.8- 25.7) | 16.9 (95% CI: 13.9-26.1) |
| Non-MET-driven/PD-L1+ | 22% (2/9) | 2.7 (95% CI: 0.0- 7.2) | 12.3 (95% CI: 9.1-21.6) |
| MET-driven/TMB ≥ median | 57% (4/7) | 11.99 (95% CI: 6.4-9.9) | 21.3 (95% CI: 0.3-42.2) |
| MET-driven/TMB <median | 40% (4/10) | 9.1 (95% CI: 6.3-11.9) | 15.7 (95% CI: 11.3-20.1) |
| MET-driven/PD-L1+/TMB ≥ median | 50% (3/6) | 14.3 (95% CI: 8.6-20.0) | 18.5 (95% CI: 11.5-25.4) |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 725)
DOI
10.1200/JCO.2023.41.6_suppl.725
Abstract #
725
Poster Bd #
K20
Abstract Disclosures
Similar Abstracts
Abstract
2022 ASCO Annual Meeting
CALYPSO: A three-arm randomized phase II study of durvalumab alone or with savolitinib or tremelimumab in previously treated advanced clear cell renal cancer.
First Author: Thomas Powles
Abstract
2021 ASCO Annual Meeting
Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.
First Author: Cristina Suarez Rodriguez
Abstract
2024 ASCO Gastrointestinal Cancers Symposium
Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using 18F-BMS-986229 PET.
First Author: Samuel Louis Cytryn
Abstract
2019 Genitourinary Cancers Symposium
A phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO).
First Author: Thomas Powles